WEBULL
WebtradeDownload

Earnings Growth Could Change The Case For Nuvation Bio Stock (NUVB)

Simply Wall St · 1d ago
  • Nuvation Bio reported third quarter 2026 revenue of US$44.95 million and a net loss of US$41.9 million, with basic loss per share from continuing operations of US$0.12.
  • Across the first nine months of 2026, the business generated US$159.87 million in revenue while narrowing its net loss to US$99.34 million, supported by an updated IBTROZI label that highlights a long median treatment duration.
  • We will now look at how Nuvation Bio's higher revenue base and reduced losses may influence the broader investment narrative.

Scan beyond Nuvation Bio's earnings and treatment profile, and size up other early-stage healthcare names with chronic-style revenue potential using the hand-picked 35 healthcare AI stocks.

Nuvation Bio Investment Narrative Recap

To own Nuvation Bio, you need to be comfortable with a story built around IBTROZI as the primary commercial engine and safusidenib as a long dated second pillar. The latest quarter showed revenue of US$44.95 million and a net loss of US$41.9 million. That mix keeps the focus on execution, not yet on bottom line strength.

Across the first nine months of 2026, revenue of US$159.87 million and a narrowed loss of US$99.34 million suggest management is scaling IBTROZI while still spending heavily on R&D. The analyst consensus narrative on Simply Wall St highlights safusidenib timing risk, so the key near term catalyst remains IBTROZI uptake and label utility, with competitive ROS1 drugs as the main operational threat.

The most relevant update here is the expanded IBTROZI label in the U.S. It now highlights a nearly 50 month median duration of response in TKI naive ROS1 positive non small cell lung cancer. That label detail supports the idea of a chronic style therapy, where each treated patient can stay on drug for an extended period if they respond.

For investors, this connects directly to catalysts around revenue quality rather than just headline growth. A longer documented treatment duration, paired with the reported revenue of US$44.95 million in the quarter and US$159.87 million year to date, helps frame IBTROZI as a potentially steadier cash generator while Nuvation Bio works through the long safusidenib Phase III and global IBTROZI reimbursement efforts.

Nuvation Bio's narrative projects forecast revenue of US$469.0 million and earnings of US$10.6 million by 2029. This implies revenue growth of 40.3% per year and an earnings increase of about US$160 million from current earnings of a US$149.8 million loss.

Uncover why Nuvation Bio's fair value indicates a 223% potential upside to its current price, which could narrow quickly.

NYSE:NUVB 1-Year Stock Price Chart
NYSE:NUVB 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts anchor their thesis on safusidenib becoming a sizeable earnings engine for Nuvation Bio, with projections before this earnings report that revenue could reach US$757.3 million and profit could climb to US$266.7 million by 2029. That is far more upbeat than consensus and shows how widely views can differ. These scenarios were set before the latest IBTROZI and earnings update, so treat them as starting points and explore a range of opinions before deciding what you think might change next.

Explore 3 other Nuvation Bio fair value estimates, including one that suggests as much as 1097% upside from the current price!

Decide For Yourself

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

  • A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards that could impact your investment decision.
  • See our latest analysis for Nuvation Bio. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nuvation Bio's overall financial health at a glance.

Looking For More Investment Ideas Beyond Nuvation Bio?

Once you have a handle on Nuvation Bio, it can help to compare it with other opportunities that fit different risk and income profiles. The Simply Wall St Screener lets you do that quickly by filtering for specific traits that match your own approach.

  • If you want to focus on steadier balance sheets first, start with a list of solid balance sheet and fundamentals (23 results) so you can compare Nuvation Bio with companies that prioritise financial resilience.
  • For readers hunting for potential value situations, you can scan a 32 high quality undervalued stocks and weigh those candidates against Nuvation Bio's current narrative.
  • Income seekers who prefer cash returns can check out a 6 dividend fortresses and see how higher yielding stocks stack up beside a development focused business like Nuvation Bio.